News & Events about 4d Molecular Therapeutics Inc.
Expands Large Market Ophthalmology Portfolio Following Positive Clinical Data in wet Age-Related Macular Degeneration to Include Diabetic Macular Edema Clinical Program and Geographic Atrophy Preclinical ProgramExpands Large Market Pulmonology Portfolio Following Positive Clinical Data in Cystic ...
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT Get Rating) CEO David Kirn sold 32,933 shares of the businesss stock in a transaction dated Thursday, December 15th. The stock was sold at an average price of $23.59, for a total transaction of $776,889.47. Following the completion of the ...
4D Molecular Therapeutics (NASDAQ:FDMT Get Rating) and Orchard Therapeutics (NASDAQ:ORTX Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, analyst ...
Latest Ratings for FDMT
DateFirmActionFromTo Jan 2022SVB LeerinkInitiates Coverage OnOutperform Jan 2021B of A SecuritiesInitiates Coverage OnBuy Jan 2021Goldman SachsInitiates Coverage OnNeutral
View More Analyst Ratings for FDMT
View the Latest Analyst Ratings
read more...
Globe Newswire
3 months ago
Cohort 1 lung bronchoscopy sample results demonstrate widespread delivery and expression of the 4D-710 CFTRR transgene in 100% of samples from all three patients Cohort 1 safety and tolerability of 4D-710 demonstrated to date, with no drug-related adverse events following aerosol deliveryCohort 1 ...